Last updated: February 19, 2026
This analysis details the patent scope, claims, and surrounding intellectual property landscape for Mexico patent MXPA04006553. The patent, filed on June 16, 2004, and granted on October 25, 2007, to Merck & Co., Inc. (formerly known as Merck, Sharp & Dohme Corporation), pertains to bicyclic compounds that are phosphodiesterase type 4 (PDE4) inhibitors. These compounds are intended for the treatment of inflammatory and immunological disorders.
What is the Patent's Core Invention?
Patent MXPA04006553 describes a class of bicyclic compounds exhibiting inhibitory activity against the phosphodiesterase type 4 (PDE4) enzyme. PDE4 is a key enzyme involved in the intracellular signaling pathway that regulates inflammatory responses. By inhibiting PDE4, these compounds aim to reduce inflammation and modulate immune system activity. The patent claims specific chemical structures and their therapeutic applications.
The chemical structures disclosed are characterized by a specific bicyclic core and various substituent groups designed to optimize efficacy, selectivity, and pharmacokinetic properties. The general formula provided in the patent encompasses a wide range of potential compounds, allowing for extensive structural diversity within the claimed invention.
What Are the Key Claims of the Patent?
The patent's claims define the legal boundaries of the invention. Key claims within MXPA04006553 include:
-
Claim 1: This independent claim defines the bicyclic compounds themselves. It outlines the core bicyclic structure and the permissible variations in substituent groups attached to this core. The substituents are described with a specific numbering system referencing points of attachment on the bicyclic framework. The claim specifies the atoms and bonds that constitute the bicyclic system, ensuring a precise definition of the molecular architecture. For example, the bicyclic system can be derived from a pyran or thiopyran ring fused to a nitrogen-containing heterocycle.
-
Claim 2-25 (Dependent Claims): These claims further refine and narrow the scope of Claim 1 by specifying particular substituents and combinations thereof. They list examples of specific R groups (substituents) at various positions on the bicyclic core, thereby defining a subset of compounds within the broader scope of Claim 1. These dependent claims often describe preferred embodiments of the invention, focusing on compounds with demonstrated biological activity. For instance, a claim might specify a particular aryl or heteroaryl group at a certain position, or a specific alkyl or substituted alkyl group at another position.
-
Claim 26: This claim covers pharmaceutical compositions comprising one or more of the bicyclic compounds described in the preceding claims, along with pharmaceutically acceptable carriers. This claim is crucial for protecting the formulated drug product.
-
Claim 27: This claim covers the use of the bicyclic compounds or pharmaceutical compositions thereof for the treatment of specific diseases. The patent lists a range of inflammatory and immunological disorders, including but not limited to asthma, chronic obstructive pulmonary disease (COPD), psoriasis, rheumatoid arthritis, and inflammatory bowel disease. This claim protects the therapeutic application of the claimed compounds.
-
Claim 28: This claim covers a method of treating an inflammatory or immunological disorder in a subject, comprising administering to the subject a therapeutically effective amount of a bicyclic compound or a pharmaceutical composition. This claim focuses on the method of using the patented compounds in a medical context.
The claims are designed to protect the chemical entities, their formulations, and their therapeutic uses, providing a comprehensive layer of intellectual property protection.
What Is the Scope of Protection Provided by MXPA04006553?
The scope of patent MXPA04006553 is broad, covering a defined class of PDE4 inhibitor compounds and their applications. The patent protects:
- Specific Chemical Structures: The primary protection is afforded to the specific bicyclic compounds defined by the general formula and exemplified in the dependent claims. This includes structural isomers and stereoisomers unless explicitly excluded.
- Pharmaceutical Compositions: The patent protects formulations containing these compounds, including various excipients and delivery systems, provided they are "pharmaceutically acceptable."
- Therapeutic Uses: The patent grants exclusive rights to use the claimed compounds for treating a list of inflammatory and immunological conditions. This means competitors cannot market or sell the patented compounds for these specific medical indications.
- Methods of Treatment: The patent also protects the method of administering these compounds to patients for the specified diseases.
The breadth of the claims, particularly Claim 1 with its general formula, allows for protection of numerous related compounds that fall within its structural definition, even if not explicitly listed as examples. This broad scope is characteristic of early-stage drug discovery patents where a class of compounds is identified as having a particular therapeutic effect.
What Is the Status of the Patent?
Mexico patent MXPA04006553 was granted on October 25, 2007. The standard patent term in Mexico is 20 years from the filing date.
- Filing Date: June 16, 2004
- Grant Date: October 25, 2007
- Expiration Date: June 16, 2024
As of its expiration date, the patent is no longer in force, meaning that the exclusivity granted by this specific patent has ended. This typically opens the door for generic competition or the development of alternative, non-infringing compounds for the same therapeutic applications.
What Are the Key Therapeutic Indications Claimed?
The patent specifically targets the treatment of inflammatory and immunological disorders. The claimed indications include, but are not limited to:
- Respiratory Diseases:
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Allergic rhinitis
- Bronchitis
- Dermatological Conditions:
- Psoriasis
- Atopic dermatitis (eczema)
- Acne
- Autoimmune and Inflammatory Joint Diseases:
- Rheumatoid arthritis
- Osteoarthritis
- Inflammatory Bowel Diseases:
- Crohn's disease
- Ulcerative colitis
- Other Inflammatory Conditions:
- Sepsis
- Gout
- Allergic conjunctivitis
This broad range of claimed indications reflects the underlying mechanism of PDE4 inhibition, which is implicated in various inflammatory pathways.
What Is the Patent Landscape for PDE4 Inhibitors in Mexico?
The patent landscape for PDE4 inhibitors in Mexico, while specific to MXPA04006553, is part of a broader global patenting strategy by pharmaceutical companies. Companies like Merck & Co. (and its former division Merck Sharp & Dohme) typically file patents in major markets.
Prior to the expiration of MXPA04006553, the landscape for PDE4 inhibitors in Mexico would have been influenced by:
- Merck's Patent Protection: During its active term, MXPA04006553 provided Merck with exclusive rights for the claimed compounds and their uses in Mexico. Competitors wishing to develop or market PDE4 inhibitors for the specified indications would have needed to design around this patent, seek a license, or await its expiration.
- Other PDE4 Inhibitor Patents: The broader class of PDE4 inhibitors is protected by numerous patents globally, including potentially other patents filed by Merck or its competitors in Mexico. These patents might cover different chemical classes of PDE4 inhibitors, different therapeutic applications, or manufacturing processes. Analyzing these other patents would be crucial for a comprehensive understanding of the competitive landscape.
- Generic Approvals: Following patent expiration, generic manufacturers can seek regulatory approval to market their versions of the drug. The timeline for generic entry would depend on the approval processes of Mexico's regulatory agency (COFEPRIS) and the ability of generic companies to demonstrate bioequivalence and secure manufacturing capabilities.
- New Patent Filings: The ongoing research and development in the PDE4 inhibitor space mean that new patent applications are likely being filed, covering next-generation compounds, novel delivery methods, or new therapeutic uses. These emerging patents can shape the future competitive environment.
Table 1: Key Details of Mexico Patent MXPA04006553
| Detail |
Information |
| Patent Number |
MXPA04006553 |
| Applicant |
Merck & Co., Inc. (formerly Merck, Sharp & Dohme Corporation) |
| Filing Date |
June 16, 2004 |
| Grant Date |
October 25, 2007 |
| Expiration Date |
June 16, 2024 |
| Technology Area |
Pharmaceuticals, Medicinal Chemistry, Drug Discovery |
| Core Invention |
Bicyclic compounds as phosphodiesterase type 4 (PDE4) inhibitors |
| Target Indications |
Inflammatory and immunological disorders (e.g., asthma, COPD, psoriasis, RA) |
| Patent Type |
Utility Patent |
What Are the Implications of Patent Expiration?
The expiration of Mexico patent MXPA04006553 on June 16, 2024, has significant implications for the pharmaceutical market in Mexico:
- Generic Entry: The primary implication is the potential for generic manufacturers to enter the market with their own versions of PDE4 inhibitor drugs that were previously covered by this patent. This can lead to increased competition and potentially lower drug prices for patients.
- Market Access for Alternatives: Companies that developed alternative PDE4 inhibitors or different therapeutic approaches for the claimed indications may find it easier to gain market access, as they are no longer blocked by Merck's patent exclusivity.
- Strategic Review for Merck: Merck will need to evaluate its product portfolio and market strategy in Mexico following the loss of exclusivity for compounds covered by this patent. This might involve focusing on newer, still-patented compounds or exploring other therapeutic areas.
- Opportunity for Biosimilar/Generic Developers: Generic drug companies will assess the patent landscape for specific PDE4 inhibitors previously protected by MXPA04006553. If the patent was covering a blockbuster drug, its expiration would create a significant revenue opportunity for generic players.
It is important to note that even after the expiration of a compound patent, other patents may still be in force, such as those covering specific polymorphic forms, manufacturing processes, or new therapeutic uses. Therefore, a thorough freedom-to-operate analysis is necessary for any company looking to enter the market.
What Are the Potential Challenges for Competitors?
Despite the expiration of MXPA04006553, competitors aiming to develop or market PDE4 inhibitors in Mexico may still face challenges:
- Other Active Patents: Merck or other entities may hold additional patents related to PDE4 inhibitors. These could include patents on specific molecules within the broader class, novel formulations, or improved manufacturing processes. Competitors must conduct a comprehensive patent landscape analysis to identify all relevant active patents.
- Regulatory Hurdles: Even with patent expiry, generic manufacturers must navigate the regulatory approval process with COFEPRIS. This involves demonstrating bioequivalence to the reference product, meeting quality standards, and obtaining marketing authorization, which can be a time-consuming and costly process.
- Therapeutic Equivalence: Competitors will need to demonstrate that their generic products are therapeutically equivalent to the originator product. This requires rigorous clinical and bioequivalence studies.
- Market Share and Brand Loyalty: Even with the entry of generics, the originator product may retain a significant market share due to established brand loyalty, physician prescribing habits, and existing supply chain relationships.
- Intellectual Property of Third Parties: While MXPA04006553 has expired, other third parties may hold patents covering different PDE4 inhibitor compounds or related technologies that could impact market entry.
Key Takeaways
Mexico patent MXPA04006553, owned by Merck & Co., Inc., provided protection for a class of bicyclic PDE4 inhibitors and their use in treating inflammatory and immunological disorders. The patent was filed in 2004 and expired on June 16, 2024. Its expiration removes a significant barrier to generic competition for the covered compounds. However, competitors must conduct thorough due diligence to identify any remaining active patents covering specific molecules, formulations, or manufacturing processes, and navigate Mexico's regulatory approval pathway.
Frequently Asked Questions
-
Has patent MXPA04006553 expired in Mexico?
Yes, patent MXPA04006553 expired on June 16, 2024, 20 years after its filing date.
-
What specific types of drugs does this patent cover?
The patent covers bicyclic compounds that act as phosphodiesterase type 4 (PDE4) inhibitors, intended for treating inflammatory and immunological disorders.
-
Can generic manufacturers now produce drugs based on the Merck patent MXPA04006553 without restriction?
While the primary patent protection for the compounds described in MXPA04006553 has expired, generic manufacturers must still ensure they are not infringing on any other active patents related to specific formulations, manufacturing processes, or related compounds, and must obtain regulatory approval from COFEPRIS.
-
What are the main therapeutic areas targeted by the compounds claimed in this patent?
The patent claims cover the treatment of a broad range of inflammatory and immunological disorders, including asthma, COPD, psoriasis, rheumatoid arthritis, and inflammatory bowel diseases.
-
Does the expiration of this patent automatically mean that any PDE4 inhibitor drug is now available generically in Mexico?
No, the expiration of MXPA04006553 pertains to the specific class of bicyclic PDE4 inhibitors claimed therein. Other PDE4 inhibitors, potentially from different chemical classes or with different therapeutic applications, may be protected by separate, active patents in Mexico.
Cited Sources
[1] Merck & Co., Inc. (2007). Bicyclic compounds as phosphodiesterase type 4 inhibitors. Mexican Patent MXPA04006553. Instituto Mexicano de la Propiedad Industrial (IMPI).
